The HK$100 million repurchase plan has launched the “first shot”! Rebon Pharmaceutical-B (09637)'s first repurchase of nearly HK$1 million landed

The Zhitong Finance App learned that on November 2, 2026, Rebang Pharmaceutical (09637) issued an announcement. The company purchased 583,000 shares on the Hong Kong Stock Exchange open market on the same day, with a repurchase amount of about HK$995,900. The average repurchase price per share was about HK$17.08, and the repurchase price ranged from HK$16.57 to HK$17.19.

On the same day, the full-day turnover of Rebang Pharmaceutical Co., Ltd. was approximately HK$11.844,600, an increase of about 12% over the previous five trading days; the daily turnover was 701,000 shares, and the number of shares repurchased on the same day accounted for about 8.3% of the daily turnover.

This repurchase is a concrete implementation of the repurchase plan previously announced by the company. On October 20, 2026, Rebang Pharmaceuticals announced that it will repurchase H shares in the open market according to the general authorization granted by shareholders at the EGM, depending on market conditions, with a total repurchase limit of HK$100 million, including brokerage commissions, stamp duty and other related transaction fees.

According to the announcement, all of the repurchase funds come from the company's own funds, and proceeds from the global sale will not be used; all or part of the purchased H shares will be cancelled and/or held as treasury shares. The company also stated that it may make further repurchases within the scope of the applicable authorization according to market conditions.

Libang Pharmaceutical focuses on kidney disease and related chronic diseases. The product portfolio covers the different stages and complications of chronic kidney disease. Its commercialized product, Mexilla®, is a long-acting erythropoietin stimulant (ESA) used to treat anemia associated with chronic kidney disease. In the first half of 2026, sales of this product were 24.8 million yuan, an increase of about 105% over the previous year.

In terms of research and development, the company expects several pipelines to continue to make progress from the second half of 2026 to 2027. Among them, the Chinese new drug application for the marketing of AP301, a drug selected for hyperphosphatemia, has entered the registration review, and a global phase IIb multi-regional clinical trial of AP306, another drug selected for hyperphosphatemia, is underway.

The dual PPAR agonist AP303 will initiate screening for diabetic nephropathy and IgA nephropathy phase II basket phase II trials and simultaneously prepare for phase II clinical trials of autosomal dominant polycystic kidney disease (ADPKD) and focal segmental glomerulosclerosis (FSGS). The candidate drug for IgA nephropathy AP308 was approved by the US Food and Drug Administration (FDA) to conduct clinical trials (IND) in September 2026, and phase I clinical trials are scheduled to begin in the near future.